NewAmsterdam Pharma (NASDAQ:NAMS) Shares Down 6.9% – What’s Next?

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) shares fell 6.9% during trading on Wednesday . The stock traded as low as $24.25 and last traded at $23.8690. Approximately 167,541 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 1,045,328 shares. The stock had previously closed at $25.63.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on NAMS shares. BMO Capital Markets initiated coverage on NewAmsterdam Pharma in a research report on Monday, July 20th. They set an “outperform” rating and a $58.00 price target for the company. Royal Bank Of Canada cut their price objective on shares of NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $45.00 price objective on shares of NewAmsterdam Pharma in a report on Monday, July 20th. HC Wainwright reiterated a “buy” rating and issued a $52.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $49.73.

NewAmsterdam Pharma Price Performance

The company has a market cap of $2.79 billion, a PE ratio of -10.82 and a beta of 0.09. The stock has a fifty day moving average price of $29.34 and a 200-day moving average price of $31.45.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The business had revenue of $3.70 million during the quarter, compared to analyst estimates of $2.83 million. NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. On average, equities analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.82 earnings per share for the current year.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Kooij sold 105,000 shares of the business’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $30.34, for a total value of $3,185,700.00. Following the transaction, the chief accounting officer owned 24,353 shares in the company, valued at $738,870.02. The trade was a 81.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Johannes Kastelein sold 125,000 shares of the firm’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $26.91, for a total value of $3,363,750.00. Following the sale, the insider directly owned 69,302 shares of the company’s stock, valued at $1,864,916.82. This trade represents a 64.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 270,000 shares of company stock worth $7,757,450 in the last 90 days. Corporate insiders own 12.74% of the company’s stock.

Institutional Trading of NewAmsterdam Pharma

A number of institutional investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN raised its holdings in shares of NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after purchasing an additional 300 shares in the last quarter. KBC Group NV acquired a new position in NewAmsterdam Pharma during the first quarter worth $37,000. Navalign LLC bought a new position in NewAmsterdam Pharma during the fourth quarter valued at about $46,000. AdvisorNet Financial Inc bought a new position in shares of NewAmsterdam Pharma in the 1st quarter valued at approximately $82,000. Finally, Empowered Funds LLC acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter worth $85,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.